<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="23" ids="18059">Lipid</z:chebi>-lowering fibrate drugs are known to affect the synthesis of fatty acids, which may alter the prostacyclin synthesis in diabetic patients </plain></SENT>
<SENT sid="1" pm="."><plain>Therefore, the serum levels of precursor fatty acids and 6-keto-<z:chebi fb="0" ids="28852">prostaglandin F1alpha</z:chebi> (6-keto <z:chebi fb="0" ids="28852">PGF1alpha</z:chebi>) were determined in ten hyperlipidemic patients with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> before and after administration of <z:chebi fb="0" ids="5296">gemfibrozil</z:chebi> (900 mg/day) for 3 months, in comparison with the results in seven non-diabetic hyperlipidemic patients </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="5296">Gemfibrozil</z:chebi> significantly reduced the serum concentration of dihomo-7-<z:chebi fb="0" ids="25048,27432">linolenic acid</z:chebi>, total cholesterol and <z:chebi fb="4" ids="17855">triglycerides</z:chebi>, but did not affect the serum levels of <z:chebi fb="0" ids="15843">arachidonic acid</z:chebi> and 6-keto <z:chebi fb="0" ids="28852">PGF1alpha</z:chebi> in diabetic and non-diabetic patients </plain></SENT>
<SENT sid="3" pm="."><plain>Thus, <z:chebi fb="0" ids="5296">gemfibrozil</z:chebi> did not affect the synthesis of prostacyclin in spite of the reduction of precursor fatty acids in diabetic and non-diabetic patients </plain></SENT>
</text></document>